Founded by Professor Anthony Molteno®, whose ground-breaking glaucoma research has resulted in the hugely successful Molteno® glaucoma implants that are used worldwide today.
Molteno® glaucoma implants are the most refined, most effective and most studied glaucoma drainage devices in the world with clinical research in thousands of patients over thirty years . The Molteno3® implants distil that research into a single device that is slimmer, easier to implant and as effective at reducing intraocular pressure than competing devices .
Molteno® implants are produced in a purpose built facility In Dunedin, New Zealand to the highest levels of tolerance and sterility and meet strict ISO 13485, and CE 0344 standards.
AlexMed is introducing the new generation
Molteno3® S-series Single Plate Implant (SS & SL)
Molteno® Ophthalmic Ltd manufactures the most versatile, safe and effective glaucoma drainage devices with the longest and most comprehensive follow-up of any glaucoma devices on the market . Glaucoma drainage devices are also known as glaucoma shunts, drains or implants
Many leading glaucoma surgeons now prefer the Molteno3® S-series implants which feature:
The Molteno3® implant range is usually used with an absorbable suture ligature (Vicryl® tie, to delay drainage, except when treating urgent cases of acutely raised intraocular pressure, neovascular glaucoma, silicone oil induced glaucoma and a few cases where inflammatory exudate or blood is present in the eye.
Hypotensive medication before and after Molteno® Implant surgery:
Control the intraocular pressure (IOP) optimally to minimise operative complications.From surgery until the onset of drainage:
Maintain the IOP in the mid-range, around 15mmHg is ideal in most cases.Once drainage commences, and in all cases with immediate drainage:
Control inflammation, if present, and allow the IOP to rise above 15mmHg (above the episcleral venous pressure). This triggers the process which lea¬ds to a more permeable bleb capsule and long-term control of IOP.From 3 months postoperatively:
Aim to keep the IOP in the low-normal range (8-12mmHg). When the IOP is well controlled in the months and years after Molteno® Implant surgery, using hypotensive agents if necessary, there is a tendency for increasing permeability of the bleb lining to occur over the long term, reducing the IOP further and decreasing the need for hypotensive medication.CAUTION:
Up to 3 months after Molteno® implant surgery, miotics, prostaglandin analogues and other topical vasodilating agents should be used with caution as they may increase the episcleral venous pressure and thus increase fibrous tissue deposition and the likelihood of bleb failure.
Medical management to promote successful outcomes long term
The Molteno® 3 Glaucoma Implant for effective long term control of IOP
Surgical Demonstration by Prof. Anthony Molteno®